# Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

> **NCT05303376** · PHASE1,PHASE2 · COMPLETED · sponsor: **Immune Biosolutions Inc** · enrollment: 123 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** IBIO123
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05303376
- **Lead sponsor:** Immune Biosolutions Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-22
- **Primary completion:** 2023-06-27
- **Final completion:** 2023-06-27
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303376, "Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05303376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*